KeyCorp Forecasts Strong Price Appreciation for Solventum (NYSE:SOLV) Stock

Solventum (NYSE:SOLV) had its price objective lifted by research analysts at KeyCorp from $97.00 to $99.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. KeyCorp’s price objective points to a potential upside of 33.56% from the company’s previous close.

SOLV has been the subject of several other reports. Stifel Nicolaus increased their price target on shares of Solventum from $88.00 to $105.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Zacks Research cut Solventum from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 1st. BTIG Research restated a “buy” rating and set a $100.00 target price on shares of Solventum in a research report on Friday. Wall Street Zen cut shares of Solventum from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Finally, Piper Sandler reissued an “overweight” rating on shares of Solventum in a report on Wednesday, December 17th. Seven research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $91.64.

Solventum Price Performance

Shares of NYSE:SOLV opened at $74.12 on Friday. Solventum has a 12 month low of $60.70 and a 12 month high of $88.20. The firm has a market capitalization of $12.86 billion, a P/E ratio of 8.36, a P/E/G ratio of 6.85 and a beta of 0.35. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.50 and a quick ratio of 1.14. The company’s fifty day moving average price is $78.58 and its 200 day moving average price is $76.23.

Solventum (NYSE:SOLV) last issued its quarterly earnings data on Thursday, February 26th. The company reported $1.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.50 by $0.07. Solventum had a return on equity of 26.99% and a net margin of 18.69%.The company had revenue of $2 billion for the quarter, compared to analyst estimates of $1.96 billion. During the same quarter last year, the company posted $1.41 earnings per share. The business’s quarterly revenue was down 3.7% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. As a group, sell-side analysts predict that Solventum will post 6.58 earnings per share for the current fiscal year.

Solventum declared that its board has authorized a stock repurchase plan on Thursday, November 20th that permits the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization permits the company to repurchase up to 7.5% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board of directors believes its stock is undervalued.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Independent Franchise Partners LLP increased its holdings in Solventum by 74.2% in the second quarter. Independent Franchise Partners LLP now owns 10,141,066 shares of the company’s stock valued at $769,098,000 after buying an additional 4,320,342 shares during the last quarter. Norges Bank acquired a new position in Solventum during the 4th quarter worth $147,467,000. Diamond Hill Capital Management Inc. increased its stake in Solventum by 152.2% during the 4th quarter. Diamond Hill Capital Management Inc. now owns 2,109,027 shares of the company’s stock valued at $167,119,000 after buying an additional 1,272,921 shares during the period. Boston Partners raised its holdings in Solventum by 26.1% during the third quarter. Boston Partners now owns 4,630,300 shares of the company’s stock worth $338,006,000 after purchasing an additional 959,543 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Solventum by 5.3% in the 3rd quarter. Vanguard Group Inc. now owns 17,121,198 shares of the company’s stock worth $1,249,847,000 after buying an additional 867,837 shares in the last quarter.

Trending Headlines about Solventum

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Q4 beat — SOLV reported $1.57 EPS and $2.0B revenue, topping estimates with strong demand in surgical/wound-care products, supporting the case for continued organic growth. Read More.
• Positive Sentiment: FY2026 guidance nudged above consensus — management set EPS guidance of $6.40–$6.60, slightly ahead of Street expectations, giving some visibility to full‑year earnings. Read More.
• Positive Sentiment: Analyst bullish signals — KeyCorp raised its price target to $99 (overweight) and BTIG reaffirmed a buy with a $100 target, reflecting upside from better-than-expected results and long-term growth potential. Read More. Read More.
• Neutral Sentiment: Full disclosure for investors — the earnings call transcript and slide deck are available for deeper review of segment performance and cost drivers. Read More.
• Negative Sentiment: Margin pressure — several reports and the company’s commentary highlighted declining margins and cost headwinds despite organic sales growth (organic sales +3.5%, overall sales -3.7% y/y), which is the primary driver of investor concern. Read More.
• Negative Sentiment: Analyst caution — Wells Fargo cut its price target to $83 and moved to an equal‑weight stance, signaling shorter-term skepticism that likely amplified selling after the print. Read More.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.